Clinical Trials Logo

Unresectable Paraganglioma clinical trials

View clinical trials related to Unresectable Paraganglioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02721732 Active, not recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Start date: August 15, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.

NCT ID: NCT02302833 Active, not recruiting - Clinical trials for Metastatic Adrenal Gland Pheochromocytoma

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Start date: February 17, 2015
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by surgery. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.